![Giovanni Mariggi](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Giovanni Mariggi
Direttore/Membro del Consiglio presso AURA BIOSCIENCES, INC.
Profilo
Giovanni Mariggi is the founder of Medicxi Ventures (Jersey) Ltd., which was founded in 2012.
He held the title of Associate from 2012 to 2014.
Dr. Mariggi is currently the Chairman of Vaderis Therapeutics AG.
He is also an Independent Non-Executive Director at Aura Biosciences, Inc. since 2019, a Director at Janpix Holdings, Inc., Fore Biotherapeutics, Inc., Vicebio Ltd., and Ateda Therapeutics Ltd., and a Member-Supervisory Board at Gadeta BV.
Dr. Mariggi previously worked as a Principal at Index Ventures SA from 2015 to 2016.
He received his undergraduate degree from Imperial College London and his doctorate degree from University College London.
Posizioni attive di Giovanni Mariggi
Società | Posizione | Inizio |
---|---|---|
AURA BIOSCIENCES, INC. | Direttore/Membro del Consiglio | 01/04/2019 |
Medicxi Ventures (Jersey) Ltd.
![]() Medicxi Ventures (Jersey) Ltd. Investment ManagersFinance Medicxi Ventures (Jersey) Ltd. (Medicxi) is an independent venture capital firm founded in 2016 by Francesco de Rubertis, Michèle Ollier, and Kevin S. Johnson. The firm is headquartered in London. | Fondatore | - |
Gadeta BV
![]() Gadeta BV Medical SpecialtiesHealth Technology Gadeta BV discovers and develops novel cancer immunotherapies. It provides groundbreaking discoveries regarding the role of cell receptors in the broad of heamatological and solid tumor cells. The firm develops t-cells engineered to express a defined gamma delta, an anti- cancer product that eradicates tumors. The company was founded by Jurgen Kuball in 2015 and is headquartered in Utrecht, Netherlands. | Direttore/Membro del Consiglio | - |
Janpix Holdings, Inc.
![]() Janpix Holdings, Inc. Miscellaneous Commercial ServicesCommercial Services Janpix Holdings, Inc. engages in provision of research and experimental development on biotechnology. The company was founded by Patrick T. Gunning and Cortes Pierre and is headquartered in Cambridge, MA. | Direttore/Membro del Consiglio | - |
Vaderis Therapeutics AG
![]() Vaderis Therapeutics AG BiotechnologyHealth Technology Vaderis Therapeutics AG is a clinical stage biotech company based in Basel, Switzerland. The Swiss company aims to develop medicinal treatments for rare and orphan diseases associated with vascular malformations. The company focuses on developing a medicine for the treatment of HHT and other diseases associated with vascular malformations. HHT is a rare disease that causes vascular overgrowth due to genetic mutations, and there are no drugs approved anywhere in the world that specifically treat it. The company was founded in 2019 by Nicholas Benedict, Pierre Saint-Mezard, and Damien Picard, and Nicholas Benedict has been the CEO since incorporation. Vaderis raised a series a financing from Medicxi and acquired a portfolio of allosteric Akt inhibitors from Almac Discovery Ltd. | Presidente | - |
Fore Biotherapeutics, Inc.
![]() Fore Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Fore Biotherapeutics, Inc. develops tumor specific driver mutations. It offers fully automated live-cell screening from NGS data. The company was founded by Haim Gil-Ad and Yoram Altschuler in 2011 and is headquartered in Philadelphia, PA. | Direttore/Membro del Consiglio | 23/08/2023 |
Vicebio Ltd. | Direttore/Membro del Consiglio | - |
Precedenti posizioni note di Giovanni Mariggi
Società | Posizione | Fine |
---|---|---|
Index Ventures SA
![]() Index Ventures SA Investment ManagersFinance Index Ventures SA (Index Ventures) is a venture capital firm founded in 1996 by Neil Alexander Rimer, Gluseppe Zocco and Gerald Rimer. The firm is headquartered in Geneva, Switzerland. | Analista di Private Equity | 31/01/2016 |
Formazione di Giovanni Mariggi
University College London | Doctorate Degree |
Imperial College London | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 1 |
---|---|
AURA BIOSCIENCES, INC. | Health Technology |
Aziende private | 7 |
---|---|
Index Ventures SA
![]() Index Ventures SA Investment ManagersFinance Index Ventures SA (Index Ventures) is a venture capital firm founded in 1996 by Neil Alexander Rimer, Gluseppe Zocco and Gerald Rimer. The firm is headquartered in Geneva, Switzerland. | Finance |
Medicxi Ventures (Jersey) Ltd.
![]() Medicxi Ventures (Jersey) Ltd. Investment ManagersFinance Medicxi Ventures (Jersey) Ltd. (Medicxi) is an independent venture capital firm founded in 2016 by Francesco de Rubertis, Michèle Ollier, and Kevin S. Johnson. The firm is headquartered in London. | Finance |
Gadeta BV
![]() Gadeta BV Medical SpecialtiesHealth Technology Gadeta BV discovers and develops novel cancer immunotherapies. It provides groundbreaking discoveries regarding the role of cell receptors in the broad of heamatological and solid tumor cells. The firm develops t-cells engineered to express a defined gamma delta, an anti- cancer product that eradicates tumors. The company was founded by Jurgen Kuball in 2015 and is headquartered in Utrecht, Netherlands. | Health Technology |
Janpix Holdings, Inc.
![]() Janpix Holdings, Inc. Miscellaneous Commercial ServicesCommercial Services Janpix Holdings, Inc. engages in provision of research and experimental development on biotechnology. The company was founded by Patrick T. Gunning and Cortes Pierre and is headquartered in Cambridge, MA. | Commercial Services |
Vaderis Therapeutics AG
![]() Vaderis Therapeutics AG BiotechnologyHealth Technology Vaderis Therapeutics AG is a clinical stage biotech company based in Basel, Switzerland. The Swiss company aims to develop medicinal treatments for rare and orphan diseases associated with vascular malformations. The company focuses on developing a medicine for the treatment of HHT and other diseases associated with vascular malformations. HHT is a rare disease that causes vascular overgrowth due to genetic mutations, and there are no drugs approved anywhere in the world that specifically treat it. The company was founded in 2019 by Nicholas Benedict, Pierre Saint-Mezard, and Damien Picard, and Nicholas Benedict has been the CEO since incorporation. Vaderis raised a series a financing from Medicxi and acquired a portfolio of allosteric Akt inhibitors from Almac Discovery Ltd. | Health Technology |
Fore Biotherapeutics, Inc.
![]() Fore Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Fore Biotherapeutics, Inc. develops tumor specific driver mutations. It offers fully automated live-cell screening from NGS data. The company was founded by Haim Gil-Ad and Yoram Altschuler in 2011 and is headquartered in Philadelphia, PA. | Health Technology |
Vicebio Ltd. |
- Borsa valori
- Insiders
- Giovanni Mariggi